South Wales, Sept. 24 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "MYRIAD ONCOLOGY" on Sept. 5. The details about the trademark application no. UK00004259806 published in the journal no. 2025/038 (Sept. 19).
With HGF Limited as representative, Myriad Genetics, Inc. filed the trademark application for the below mentioned good(s)/service(s).
Class 10 : Medical test kit related to oncology comprising specimen collection containers, printed instructions and test forms, materials for transmitting specimens, and printed user information inserts.
Class 41 : Providing online publications, namely, questionnaires for medical screening for diagnostic or treatment purposes.
Class 42 : Providing temporary use of non-downloadable software for use in medical screening for diagnostic or treatment purposes; Software as a service (SAAS) services featuring software for use in medical screening for diagnostic or treatment purposes.
Class 44 : Medical testing services related to oncology; genetic and genomic testing related to oncology; genetic testing for medical purposes; genetic testing services for diagnostic or treatment purposes; genetic counseling; medical diagnostic testing, monitoring, and reporting services; providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; diagnostic testing for the detection of cancer to assess the presence or absence of residual disease; health assessment services; providing personalized healthcare and medical information, namely, providing medical information and reports; providing medical information, consultancy and advisory services; health evaluation services, namely performing health assessments and health screening for purposes of determining medical risks and further testing.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004259806
Disclaimer: Curated by HT Syndication.
